L Gu, X Jin, H Liang, C Yang, Y Zhang - Pharmacological Research, 2023 - Elsevier
Oral multitarget tyrosine kinase inhibitors (TKIs), such as sorafenib, which suppress tumor
cell proliferation and tumor angiogenesis, have been approved to treat patients with …